Compare VLY & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VLY | SYRE |
|---|---|---|
| Founded | 1927 | 2013 |
| Country | United States | United States |
| Employees | 3675 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 6.5B |
| IPO Year | N/A | 2015 |
| Metric | VLY | SYRE |
|---|---|---|
| Price | $14.41 | $83.43 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | $14.65 | ★ $85.08 |
| AVG Volume (30 Days) | ★ 5.8M | 886.6K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.58 | N/A |
| Revenue Next Year | $8.51 | N/A |
| P/E Ratio | $13.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.36 | $13.93 |
| 52 Week High | $14.70 | $84.43 |
| Indicator | VLY | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 64.69 | 64.66 |
| Support Level | $13.30 | $66.78 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.29 | 4.35 |
| MACD | 0.08 | 0.68 |
| Stochastic Oscillator | 76.87 | 91.85 |
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.